within Pharmacolibrary.Drugs.ATC.R;

model R02AA20
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 0 / 1000000,
    adminCount     = 1,
    Vd             = 0,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>This ATC code (R02AA20) refers to 'Combinations' of local agents for throat preparations, specifically antiseptics used in the treatment of sore throat or minor mouth infections. The 'various' designation indicates that this is not a single substance, but rather different combinations of locally-acting agents that may include antiseptics, local anesthetics, or antibiotics in lozenge, spray, or solution form. These combinations are generally used for symptomatic relief of irritation and pain in the throat and are available over the counter in many countries.</p><h4>Pharmacokinetics</h4><p>No peer-reviewed pharmacokinetic data is specifically reported for combination products categorized under ATC code R02AA20 (various 'Throat Preparations' combinations). These products often contain locally-acting agents where systemic absorption is minimal or not therapeutically relevant. Thus, pharmacokinetic parameters are not typically reported or required.</p><h4>References</h4><ol><li><p>Schnider, LK, et al., &amp; Landolt, HP (2025). Effects of Subanesthetic Oromucosal Dexmedetomidine on Sleep in Humans: A Randomized, Controlled Pharmacokinetics-Pharmacodynamics Study. <i>Anesthesiology</i> 142(3) 476–487. DOI:<a href=&quot;https://doi.org/10.1097/ALN.0000000000005314&quot;>10.1097/ALN.0000000000005314</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39601561/&quot;>https://pubmed.ncbi.nlm.nih.gov/39601561</a></p></li><li><p>Thijssen, E, et al., &amp; Groeneveld, GJ (2024). Clinical trial evaluating apomorphine oromucosal solution in Parkinson&#x27;s disease patients. <i>Clinical and translational science</i> 17(5) e13796–None. DOI:<a href=&quot;https://doi.org/10.1111/cts.13796&quot;>10.1111/cts.13796</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38712716/&quot;>https://pubmed.ncbi.nlm.nih.gov/38712716</a></p></li><li><p>Tian, Y, et al., &amp; Visser, JC (2019). Oromucosal films: from patient centricity to production by printing techniques. <i>Expert opinion on drug delivery</i> 16(9) 981–993. DOI:<a href=&quot;https://doi.org/10.1080/17425247.2019.1652595&quot;>10.1080/17425247.2019.1652595</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31382842/&quot;>https://pubmed.ncbi.nlm.nih.gov/31382842</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end R02AA20;
